Galera Therapeutics, LLC
St. Louis
Missouri
United States
102 articles about Galera Therapeutics, LLC
-
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung CancerTrial Supported in Part by NIH SBIR Grant
10/22/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the first patient has been dosed in the Phase 1/2 GRECO-1 clinical trial of GC4711 in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCL
-
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
9/22/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it will host a virtual Key Opinion Leader (KOL) event on locally advanced pancreatic cancer on Friday, October 2, 2020, at 11 a.m. EDT. Sarah Hoffe, M.D., will provide a review of the manageme
-
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19
9/16/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a pilot Phase 2 clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19.
-
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
9/14/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020, at 1:40 p.m. EDT.
-
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer
9/8/2020
Company Updates Guidance for Topline Data Readout to ASTRO 2020
-
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
8/10/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2020, and provided business updates.
-
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
7/30/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2020 BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 9:30 a
-
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic CancerTopline safety and efficacy data to be reported in the second half of 2020
7/13/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC).
-
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
5/29/2020
Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program
-
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
5/18/2020
Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that it will host a virtual Key Opinion Leader event on cisplatin-induced chronic kidney disease on Friday, May 22, 2020, from 10 a.m. to 11 a.m. EDT.
-
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
5/13/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective analysis of Phase 2b trial data demonstrating the potential renal protective activity of lead candidate avasopasem manganese (GC4419),
-
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
5/12/2020
ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Cash Runway into 2H22 Locally Advanced Pancreatic Cancer Phase 1b/2a Trial Topline Data Readout and Initiation of NSCLC Anti-cancer Phase 1b/2a Trial Both Remain On Track for 2H20 MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a
-
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
5/5/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the BofA Securities 2020 Health Care Conference on Tuesday, May 12, 2020, at 9:40 a.m. EDT. A live audio webc
-
Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program
4/30/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced three abstracts regarding lead candidate avasopasem manganese (GC4419) were accepted for presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
-
Galera Therapeutics Appoints Linda B. West to Board of Directors
4/2/2020
Galera Therapeutics, Inc. , today announced the appointment of Linda B. West to its board of directors. Additionally, as part of a planned transition, Jason Fuller, Ph.D., will not stand for re-election at Galera’s annual meeting. “Linda is
-
Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
3/10/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2019, and highlighted recent corporate accomplishments.
-
Clinical Catch-Up: February 24-28
3/2/2020
The month of February ended with a flurry of clinical trial announcements. Here’s a look. -
Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis
2/27/2020
Tumor outcomes results from two-year follow-up of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese to be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium
-
Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium
2/24/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a late-breaker presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium, which is taking place February 27-29, 2020, in Scottsdale, Ariz.
-
Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
2/19/2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference